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ABSTRACT: Mining of microbial genomes has revealed that
actinomycetes harbor far more biosynthetic potential for
bioactive natural products than anticipated. Activation of
(cryptic) biosynthetic gene clusters and identification of the
corresponding metabolites has become a focal point for drug
discovery. Here, we applied NMR-based metabolomics
combined with bioinformatics to identify novel C-glycosyl-
pyranonaphthoquinones in Streptomyces sp. MBT76 and to
elucidate the biosynthetic pathway. Following activation of the
cryptic qin gene cluster for a type II polyketide synthase (PKS)
by constitutive expression of its pathway-specific activator,
bioinformatics coupled to NMR profiling facilitated the
chromatographic isolation and structural elucidation of qinimycins A−C (1−3). The intriguing structural features of the
qinimycins, including 8-C-glycosylation, 5,14-epoxidation, and 13-hydroxylation, distinguished these molecules from the model
pyranonaphthoquinones actinorhodin, medermycin, and granaticin. Another novelty lies in the unusual fusion of a
deoxyaminosugar to the pyranonaphthoquinone backbone during biosynthesis of the antibiotics BE-54238 A and B (4, 5).
Qinimycins showed weak antimicrobial activity against Gram-positive bacteria. Our work shows the utility of combining
bioinformatics, targeted activation of cryptic gene clusters, and NMR-based metabolic profiling as an effective pipeline for the
discovery of microbial natural products with distinctive skeletons.
Actinomycetes are prolific sources of bioactive naturalproducts (NPs). From the roughly 18 000 known
bioactive bacterial compounds, more than 10 000 were
discovered from the actinomycete genus Streptomyces.1,2 Even
so, their biosynthetic potential is far from exhausted, though the
enthusiasm to discover new molecules produced by these
bacteria is dampened by chemical redundancy and the
consequential poor return of investment of high-throughput
screening campaigns.3−5 On a more positive note, whole
genome sequencing revealed that actinomycetes harbor
numerous silent and hence likely untapped biosynthetic gene
clusters that may not be associated with known metabolites;
indeed, even the very extensively studied model organism
Streptomyces coelicolor was shown to possess a far greater
producing potential than anticipated.6 Furthermore, bioinfor-
matics tools developed specifically for mining genome
sequences for the identification of biosynthetic gene clusters
allow the prediction of the chemical output on the basis of
accumulated biosynthetic knowledge.7,8 These developments in
genome mining mark the start of a new era of genomics-based
drug discovery, with the potential of greatly expanding the
chemical space of bioactive natural products.
A bottleneck is that many of the biosynthetic pathways
uncovered by genome sequencing are in a dormant state under
routine laboratory conditions, generally referred to as cryptic or
silent gene clusters, and specific approaches to activate their
expression are required.9,10 The transcription of genes encoding
the biosynthetic machinery for secondary metabolites in
actinomycetes involves multiple regulatory cascades and
networks.11 The regulatory signals are transmitted through
global regulatory networks and ultimately transmitted to the
pathway-specific regulatory genes that control the expression of
the biosynthetic genes.12
A promising approach is via a drug-discovery pipeline that is
based on combining bioinformatics-driven genome mining with
approaches to elicit the production of (cryptic) antibiotics,
followed by the metabolic profiling-based identification of the
bioactivity of interest. Strategies to circumvent the regulatory
networks that silence cryptic biosynthetic gene clusters and
trigger the biosynthesis of the corresponding natural product(s)
include manipulating the pleiotropic regulatory networks as
Received: May 24, 2016
Published: January 27, 2017
Article
pubs.acs.org/jnp
© 2017 American Chemical Society and
American Society of Pharmacognosy 269 DOI: 10.1021/acs.jnatprod.6b00478
J. Nat. Prod. 2017, 80, 269−277
This is an open access article published under a Creative Commons Non-Commercial No
Derivative Works (CC-BY-NC-ND) Attribution License, which permits copying and
redistribution of the article, and creation of adaptations, all for non-commercial purposes.
well as targeting pathway-specific regulators.10,13 NMR-based
metabolic profiling allows the efficient identification of the
relevant NPs within the context of the complex metabolic
matrix. The available bioinformatic information allows
prediction of the metabolite produced by the biosynthetic
gene clusters, and this knowledge can be directly related to the
1H NMR spectrum by examining the expected chemical shift
and/or splitting pattern of typical protons in the predicted
molecular motifs. In turn, as one compound usually contains
multiple 1H resonances, any unique NMR feature(s) in its
structure can be used to check for the expression of the
corresponding biosynthetic gene cluster and subsequently for
NMR-guided chromatographic separation. This should allow
scientists to bridge the gap between bioinformatics-driven gene
cluster analysis and experimental NPs discovery.14
In this study, we applied a workflow of NMR-based
metabolomics and bioinformatics to identify novel pyrano-
naphtoquinones. Constitutive expression of the pathway-
specific activator of a cryptic type II PKS gene cluster
(designated qin) in Streptomyces sp. MBT76 activated the
biosynthesis of a family of pyranonaphtoquinones with
intriguing chemical architecture. Genomics and structural
analysis identified a family of 8-C-glycosyl-pyranonaphthoqui-
nones (1−5). The qinimycins A−C (1−3) encompass
structural features of a rare 5,14-epoxidation and unprece-
dented 13-hydroxylation in pyranonaphthoquinones. In
addition, an unusual fusion of a deoxyaminosugar into a
pyranonaphthoquinone backbone was seen for the previously
described antibiotics BE-54238A (4) and BE-54238B (5).
■ RESULTS AND DISCUSSION
Identification and Activation of the Cryptic Type II
PKS Gene Cluster (qin) for Glycosylated Pyranonaph-
thoquinones. Streptomyces sp. MBT76, which originates from
the Qinling mountains in China, was previously identified as a
prolific producer of antibiotics, including those with efficacy
against multiple Gram-positive and Gram-negative multidrug
resistant pathogens.15 Further detailed metabolic character-
ization of the strain identified many natural products often with
interesting chemistry, including isocoumarins, prodiginines,
acetyltryptamine, and fervenulin, among others.16 Streptomyces
sp. MBT76 was subjected to Illumina/Solexa whole genomic
sequencing, and the genome was assembled in 13 contigs, with
a total genome size of 8.64 Mb. In total 7974 coding sequences
(CDS) were predicted using the GeneMark algorithm.17
Analysis of the contigs by AntiSMASH18 presented a possible
Table 1. Predicted Functions of the Gene Products of the Qinimycin Biosynthetic Gene Cluster (qin) of Streptomyces sp.
MBT76
CDS length putative function nearest orthologue found in aa identity accession number
1 322 dTDP-glucose 4,6-dehydratase Streptomyces sp. NRRL S-623 79% WP_031121809.1
2 359 dTDP-1-glucose synthase Streptomyces vietnamensis 69% ADO32770.1
3 280 N-methyltransferase Streptomyces clavuligerus 39% WP_003953258.1
4 365 C-glycosyltransferase Streptomyces sp. SCC 2136 48% CAF31363.2
5 385 NDP-hexose aminotransferase Streptomyces ambofaciens 72% CAM96587.1
6 421 hypothetical protein Streptomyces violaceoruber 45% CAA09645.1
7 436 NDP-hexose 2,3-dehydratase Streptomyces sp. NRRL S-623 67% WP_031121795.1
8 351 NDP-hexose 3-ketoreductase Streptomyces sp. NRRL S-623 64% WP_032774990.1
9 432 NDP-hexose-3,4-dehydratase Streptomyces lydicus 79% CBA11561.1
10 378 flavin-dependent monooxygenase Streptomyces sp. AM-7161 59% BAC79043.1
11 267 SARP family transcriptional regulator Streptomyces cyaneofuscatus 70% WP_030562180.1
12 312 polyketide cyclase Streptomyces aureofaciens 73% YP_009060633.1
13 287 4-phosphopantetheinyl transferase Streptomyces albus 45% WP_031175178.1
14 571 type I polyketide synthase component Streptomyces scabiei 44% YP_003491848.1
15 142 hydroxylacyl-CoA dehydrogenase Streptomyces sp. NRRL F-5135 69% WP_030744938.1
16 334 bifunctional cyclase/dehydratase Streptomyces lavenduligriseus 70% WP_030792829.1
17 87 acyl carrier protein Streptomyces sp. R1128 69% AAG30201.1
18 410 chain-length factor (polyketide beta-ketoacyl synthase beta subunit) Streptomyces lividans 73% WP_003973890.1
19 418 actinorhodin polyketide beta-ketoacyl synthase alpha subunit Streptomyces lavenduligriseus 85% WP_030792818.1
20 420 putative transporter Streptomyces viridochromogenes 50% WP_003988487.1
21 166 flavin reductase Streptomyces fulvoviolaceus 57% WP_052425229.1
22 261 ketoacyl reductase Streptomyces chartreusis 72% WP_01003439
23 309 hydroxylacyl-CoA dehydrogenase Streptomyces sp. NRRL S-31 67% WP_030735501.1
24 303 quinone oxidoreductase Nocardia sp. CNY236 72% WP_028476080.1
25 217 DSBA-type oxidoreductase Streptosporangium roseum 63% WP_012891327.1
26 191 dehydratase Streptomyces sp. AM-7161 55% BAC79041.1
27 576 stereospecific keto reductase Streptomyces sp. AM-7161 64% BAC79036.1
28 328 quinone oxidoreductase Streptomyces sp. AM-7161 71% BAC79039.1
29 201 NADPH-dependent FMN reductase Streptomyces sp. NRRL S-623 64% WP_031121793.1
30 402 S-adenosylmethionine synthetase Streptomyces roseoverticillatus 95% WP_030365339.1
31 339 adenosine kinase Streptomyces albulus 72% AIA08031.1
32 1167 methionine synthase Streptomyces roseoverticillatus 93% WP_030367617.1
33 312 5,10-methylenetetrahydrofolate reductase Streptomyces sp. NRRL F-5135 81% WP_030742694.1
34 473 adenosylhomocysteinase Streptomyces roseoverticillatus 90% WP_030365247.1
35 227 TetR family transcriptional regulator Streptomyces lividans 49% WP_003972639.1
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55 putative biosynthetic gene clusters specifying secondary
metabolites, 22 of which encoding polyketide synthases (PKS).
One 41 kb biosynthetic gene cluster for a type II PKS,
designated qin (Table 1) was of particular interest considering
its potential to specify pyranonaphthoquinones, a well-studied
family of aromatic polyketides with highly complex chemical
architecture and pronounced bioactivities,19,20 including the
representative members actinorhodin,21 medermycin,22 and
granaticin.23 In the qin gene cluster, besides the central PKS
genes that are responsible for the biosynthesis of the
pyranonaphthoquinone backbone, the presence of genes for
the deoxyaminosugar D-forosamine strongly suggested that the
end product should be glycosylated. This genetic organization
was similar to the clusters for the synthesis of the glycosylated
pyranonaphthoquinone medermycin in Streptomyces sp. AM-
7161 (med)22 and granaticin in Streptomyces violaceoruber Tü22
(gra).23 Coclustering of glycosylation-associated biosynthetic
genes with those for the aglycones is typical of microbial
genomes, which facilitates matching the biosynthetic gene
cluster to the corresponding NPs.24 In comparison, qin-ORF29
encoding an NADPH-dependent FMN reductase was absent in
either the med or gra biosynthetic gene clusters, and
glycosylation with a D-forosamine is unprecedented in the
pyranonaphthoquinone family. This promoted an investigation
into the potentially novel product(s) of the qin gene cluster.
Despite our previous detailed chemical investigations of
Streptomyces sp. MBT76,15,16 the corresponding molecules
had not been identified, suggesting that the gene cluster may be
cryptic under the many different growth conditions that had
been tested.
The qin gene cluster contains two putative regulatory genes,
namely, the SARP-family transcriptional regulatory gene qin-
ORF11 and the TetR-family regulatory gene qin-ORF35 (Table
1). Many pathway-specific activators for secondary metabolite
production in streptomycetes belong to the SARP family,12
while TetR-family regulators often act as repressors.25 As an
example, in the type II PKS gene cluster aur1 of Streptomyces
aureofaciens CCM 3239, which specifies the angucycline-family
auricin,26 aur1P and aur1PR3 encode SARP-family activators,27
while the tetR-type aur1R encodes a negative regulator.28 To
activate the qin gene cluster, we opted to overexpress the likely
pathway-specific activator gene qin-ORF11. For this, the gene
was amplified by PCR and inserted behind the ermE*
promoter29 in the conjugative and integrative vector
pSET152. The resulting plasmid was then integrated into the
attB site of the chromosome of MBT76 to create the
recombinant derivative MBT76-1.
NMR-Based Metabolic Profiling Expedited Character-
ization of Novel Glycosylated Pyranonaphthoquinones.
Ex-conjugant MBT76-1 and its parent MBT76 were fermented
in parallel in liquid modified NMMP media.16 After 5 days of
growth, the cultures were harvested by centrifugation and
extracted with EtOAc. The metabolites obtained were subjected
to 1H NMR profiling.30 As shown in Figure 1, MBT76-1
presented a very different metabolic profile in comparison to
the parental strain. The metabolites usually produced by the
wild-type strain, such as 1H-pyrrole-2-carboxamide, acetyltrypt-
amine, fervenulin, and 2-hydroxy-3-methoxy-benzamide,16 were
aborted in MBT76-1. While the production of 6,8-dihydroxy-3-
methyl-isocoumarin (9) was not affected by ORF11 over-
expression, its post-PKS methoxylation was hampered as shown
by the disappearance of methoxyl groups in the region δ 3.45−
4.25.16 Conversely, the 1H NMR spectra of MBT76-1 exhibited
proton resonances absent in the parental strain, indicating that
different compounds were produced. These included molecules
with characteristic NMR signals such as δ 4.45 (dd, J = 4.2, 1.8
Hz) for the methine in a substituted pyran ring and the methyl
doublet at δ 1.29 (d, J = 6.6 Hz), which were in agreement with
kalafungin (16-CH3) or 6′-deoxy-CH3 of a sugar moiety
predicted by bioinformatics. In the aromatic region, coupling
doublets at δ 8.01 (d, J = 8.4 Hz), and 6.56 (d, J = 8.4 Hz) were
indicative of an α,β-unsaturated ketone aryl moiety typical of
pyranonaphthoquinones. All these NMR features indicated that
indeed the qin gene cluster was actively expressed in MBT76-1.
In light of the substantial change in the metabolome of MBT76
and MBT76-1, we hypothesized that qin-ORF11 may control
multiple biosynthetic gene clusters for specialized metabolites.
To identify the metabolic product(s) of the qin gene cluster,
the crude extract of MBT76-1 was separated by semipreparative
HPLC-UV chromatography. The resulting fractions (Fr1−16)
were analyzed by 1H NMR spectroscopy, which showed that
Fr1 (2.1 mg) contained the sought-after deoxysugar-pyrano-
Figure 1. Comparison of 1H NMR spectra. 1H NMR (600 MHz, in CD3OD) was obtained on the crude extracts from wild-type strain Streptomyces
sp. MBT76 (bottom) and its ex-conjugant MBT76-1 (top). The presented chemical shifts are for aromatic region δ 5.4−8.1 and aliphatic region δ
1.2−4.5. The signals attributable to compounds produced in MBT76 wild type were indicated as the following: a, acetyltryptamine; b, 2-hydroxy-3-
methoxy-benzamide; p, 1H-pyrrole-2-carboxamide; f, fervenulin; mc, methoxylated isocoumarins. The signals attributable to compounds produced in
MBT76-1 were labeled according to the numbering in Figure 2, and the detailed signals assignments were summarized in Table S1. The highlighted
signals by red arrows are attributable to glycosylated pyranonaphthoquinone molecules.
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naphthoquinones. Further UHPLC-UV-ToF-HRMS analysis
confirmed Fr1 contained mainly three structurally related
compounds, with molecular formulas C23H27NO8 (1),
C23H29NO9 (2), and C24H31NO9 (3) with a relative abundance
of 6:2:1 (Figure S1). Elucidation of the final structure of major
compound 1 was done on the basis of extensive NMR analysis,
including 1H NMR, HSQC, HMBC, COSY, and APT. The 1H
NMR data for compound 1 (Table 2) presented characteristic
resonances for the bioinformatics-predicted deoxyaminosugar
forosamine, including a 6′-deoxy-CH3 doublet at δH 1.29 (d, J =
6.6 Hz), a 7′-N-CH3 singlet at δH 2.89 (s), and highly
overlapping signals for 2′,3′-deoxy-CH2 at δH 2.20−2.40. Aided
by COSY and HSQC experiments (Figure S2), the backbone of
the aglycone was confirmed as a kalafungin-type molecule, as
established by the spin system H2-2/H-3/H-4 for a γ-lactone
ring, together with two coupling protons at δH 1.41 (d, J = 6.6
Hz, H-16) and 4.93 (q, J = 6.6 Hz, H-15) for a pyran ring. The
additional two aromatic coupling doublets δH 7.65 (d, J = 8.4
Hz, H-9) and 7.25 (d, J = 8.4 Hz, H-10) indicated that the
deoxyaminosugar was linked to the aglycone through the C-8
residue of the benzene ring, which was confirmed by the
HMBC correlations (Figure S2) from H2-2′ (δH 2.30, 2.24) to
C-8 (δC 124.2) and from H-9 (δH 7.65) to C-1′ (δC 68.7).
More importantly, the key HMBC correlations from the H-13
(δH 5.48) to C-11 (δC 158.1), C-12 (δC 129.2), C-7 (δC 131.1),
C-5 (δC 60.6), C-14 (δC 68.1), and C-15 (δC 65.9)
demonstrated that the pyranonaphthoquinone skeleton of
kalafungin (6) acquired two variations, via the epoxidation of
the Δ5,14 double bond and hydroxylation of the ketone at C-13.
The stereochemistry at C-13 was established as R, based on the
NOESY correlation between H-13/H3-16, but no correlation
was observed for H-13/H-15. However, the configuration of
5,14-epoxy remained unclear. Consequently, the final structure
of major compound 1 (Figure 2) in Fr1 was elucidated as a
novel glycosylated pyranonaphthoquinone, and named qinimy-
cin A. Similar NMR spectral analyses revealed that compound 2
was a hydration product of 1 in the γ-lactone ring (Table 2),
and accordingly named qinimycin B. Though compound 3
(qinimycin C) was not resolved by NMR spectra due to its low
abundance, the additional mass of 14.0153 (Figure S1)
corresponding exactly to a CH2 unit suggested that the imide
in 2 was further methylated into a tertiary amine, because the
N-methyltransferase qin-ORF3 is able to di-methylate the
nitrogen atom of dTDP-D-forosamine in spinosyn pathway.31
The known compounds 4−14 (Figure 2) were identified in
Fr2−Fr16 by 1H NMR and/or UHPLC-UV-ToF-HRMS, and
the results were compared with spectroscopic data from the
literature (Table S1).
The qinimycins have intriguing chemical features, represent-
ing a new branch within the extensively studied pyranonaph-
thoquinone family of natural products. The 5,14-epoxidation
was previously described in pyranonaphthoquinone agly-
cones,32,33 but hydroxylation of the pyranonaphthoquinone
backbone at C-13 is unprecedented. The 8-C-glycosylation of
pyranonaphthoquinone is rare, though previously seen in the
antibiotic Sch 38519,34,35 and xiakemycin A.36 Within the
pyranonaphthoquinones, glycosylation with the deoxyamino-
sugar forosamine is uniquely seen in the qinimycins. With this
chemical architecture, the qinimycins rival the well-known
pyranonaphthoquinone glycosides medermycin22 or granati-
cin23 in terms of structural complexity. To establish if the
qinimycins might function as antimicrobials, their bioactivity
was tested using agar diffusion assays. Growth inhibition was
seen for the Gram-positive bacteria Bacillus subtilis 168 and
Table 2. 1H and 13C NMR Data for Compounds 1 and 2a
1 2
no. δC, type δH (J in Hz) δC, type δH (J in Hz)
1 177.4, C 174.4, C
2 37.3, CH2 2.91, dd (15.6, 4.2); 36.5, CH2 2.58, d (7.2)
2.40, dd (15.6, 1.8)
3 68.0, CH 4.45, dd (4.2, 1.8) 67.1, CH 4.16, m
4 74.0, CH 4.98, d (1.2) 64.0, CH 4.32, d (12.6)
5 60.6, C 63.0, C
6 194.6, C 197.1, C
7 131.1, C 131.5, C
8 124.2, C 124.1, C
9 132.2, CH 7.65, d (8.4) 132.1, CH 7.62, d (8.4)
10 121.4, CH 7.25, d (8.4) 121.3, CH 7.23, d (8.4)
11 158.1, C 158.1, C
12 129.2, C 129.3, C
13 61.0, CH 5.48, s 61.2, CH 5.43, s
14 68.1, C 67.7, C
15 65.9, CH 4.93, q (6.6) 65.7, CH 4.90, q (6.6)
16 14.1, CH3 1.41, d (6.6) 14.4, CH3 1.40, d (6.6)
1′ 68.7, CH 5.36, m 68.7, CH 5.36, m
2′ 32.1, CH2 2.30, m; 2.24, m 32.1, CH2 2.30, m; 2.24, m
3′ 22.5, CH2 2.38, m; 2.21, m 22.5, CH2 2.38, m; 2.21, m
4′ 75.0, CH 3.63, td (7.2, 1.8) 75.0, CH 3.63, td (7.2, 1.8)
5′ 63.8, CH 4.27, m 63.8, CH 4.27, m
6′ 19.9, CH3 1.29, d (6.6) 19.9, CH3 1.29, d (6.6)
7′ 39.0, CH3 2.89, s 39.0, CH3 2.89, s
a1 and 2 were recorded in CD3OD. Proton coupling constants (J) in Hz are given in parentheses. All chemical shift assignments were done on the
basis of 1D and 2D NMR techniques.
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Staphylococcus aureus CECT976, but not for Gram-negative
Escherichia coli JM109 or Pseudomonas aeruginosa PAO1, thus
establishing bioactivity against Gram-positive but not Gram-
negative bacteria (Table 3). However, assessment of the MIC
of the mixture of molecules revealed minimal inhibition
concentrations (MICs) against B. subtilis and S. aureus of 50
and 100 μg/mL, respectively. These high values are indicative
of very limited bioactivity of the qinimycins under the
conditions tested, and no further bioactivity analysis was
performed.
Proposed Biosynthetic Pathway for Qinimycins Based
on Bioinformatics Analysis. A biosynthetic model for
qinimycins is proposed on the basis of the functional
assignments from sequence analysis and the known metabolites
that are produced (Figure 3). The assembly line includes three
steps: (i) biosynthesis of an activated form of dTDP-D-
forosamine, similar to that found in the spinosyn pathway;31
(ii) assembly of the kalafungin aglycone by a minimal PKS
similar to that found in the biosynthetic gene clusters for
medermycin22 and granaticin;23 and (iii) regioselective
installing of a dTDP-D-forosamine moiety at the C-8 position
of kalafungin by a C-glycosyltransferase (most likely encoded
by qin-ORF4).
In a pilot study of actinorhodin biosynthesis, a two-
component flavin-dependent monooxygenase (FMO), encoded
by actVA-ORF5 (oxygenase) and actVB (flavin reductase), was
demonstrated to perform the two consecutive oxygenations at
C-6 and C-8.37 The FMO genes are commonly present in the
med and gra biosynthetic gene clusters for medermycin22 and
granaticin,23 respectively. The ActVA homologue Gra-21 was
Figure 2. Secondary metabolites produced by Streptomyces sp. MBT76-1. Compounds identification was done on the basis of NMR and HRMS
techniques, and their spectroscopy data were summarized in Table 2 and Table S1.
Table 3. Antimicrobial Activity of Qinimycinsa
inhibition zone (mm)
compound
no.
Bacillus
subtilis
Escherichia
coli
Staphylococcus
aureus
Pseudomonas
aeruginosa
Fr1 15 0 20 0
AMP 23 20 10 7
APRA 10 7 7 15
NC 0 0 0 0
aFor Fr1, 25 μL was spotted of a 2 mg/mL solution in methanol. For
AMP and APRA, 5 μL was spotted of a 1 mg/mL solution in miliQ
water. AMP, ampicillin; APRA, apramycin; NC, negative control
(methanol).
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Figure 3. Biosynthetic pathway of qinimycins and BE-54238A/B. (A) Organization of the qin locus in Streptomyces sp. MBT76. For annotation of
the respective gene products see Table 1. Genes for the minimal PKS (presented in black) are similar to those for biosynthesis of the
pyranonaphthoquinone kalafungin, while the eight genes in red encode enzymes for production of deoxyaminosugar D-forosamine. (B) Proposed
biosynthetic route to qinimycins. The exact function of each gene was assigned in every specific biosynthesis step. The intriguing feature for
qinimycins biosynthesis is reduction of the C-13 ketone probably catalyzed by qin-ORF29, while the pyrrole ring in the antibiotics BE-54328A/B
originated from the six-membered deoxyaminosugar forosamine.
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.6b00478
J. Nat. Prod. 2017, 80, 269−277
274
shown to be bifunctional at C-6 and C-8, whereas Med-7
monofunctionally oxygenizes the C-6 position. Interestingly,
the gene product of qin-ORF10 shows higher similarity to Med-
7 (59% aa identity) than to ActVA-ORF5 (53% aa identity),
suggesting possible monofunctionality at C-6. The single
oxygenation at C-6 leading to a pyranonaphthoquinone
skeleton is in good agreement with the subsequent C-
glycosylation for qinimycins at C-8 and medermycin at C-10,
where the selectivity of the responsible glycosyl transferase qin-
ORF4 is of great interest. Further studies33 on ActVA-ORF5/
ActVB revealed its additional in vitro epoxidation activity of
kalafungin. The co-occurrence of three qinimycins (1−3) is a
clear example of in vivo activity of a two-component FMO
encoded by qin-ORF10/qin-ORF21. Compared with the act,6
med,22 and gra23 gene clusters, qin-ORF29 encoding an
NADPH-dependent FMN reductase is unique in the qin gene
cluster. We propose that this enzyme may execute the
unprecedented reduction of the C-13 ketone.
It is noteworthy that, on the basis of the biosynthetic
pathway (Figure 3), we predict that qinimycins in addition to
compounds (1−3) are produced by Streptomyces sp. MBT76,
which may have been missed due to lower yields. For instance,
UHPLC-UV-ToF-HRMS analysis of MBT76-1 crude extract
showed molecules with the molecular formulas C23H27NO9 and
C23H25NO8 for the putative compounds 1a and 1b,
respectively. The post-PKS glycosylation of 8-C-glycosylpyr-
anonaphthoquinones BE-54238A (4) and BE-54238B (5)38
involved rearrangement of the deoxyaminosugar moiety. After
glycosylation of kalafungin into 5a, the six-membered amino
pyran ring was first rearranged into a five-membered 2H-3,4-
dihydropyrrole ring through a Mannich reaction, whereby the
gene product of qin-ORF6 might mediate the ring-opening of
the appended forosamine to a linear ketone. The newly formed
imide was then further cyclized with the aglycone quinone at C-
6 to give an intermediary iminium ion, which subsequently
underwent proton tautomerization to produce antibiotic BE-
54238A/B. Interestingly, this naturally occurring biosynthetic
pathway mimics the total synthesis of BE-54238B from
rhamnose.39,40 The anthraquinones 11-O-methyl-aloesaponarin
II (8) and 3,8-dihydroxy-1-methyl-anthraquinone-carboxylic
acid (9) were shunt products of the kalafungin biosynthetic
pathway,41 but it remains unclear whether polyketide molecules
10−12 were also derived from the qin gene cluster.
■ CONCLUSIONS
The replication issues that have frustrated high-throughput
screening regimes necessitate new approaches to expand the
chemical diversity of natural products and keep filling the
discovery pipelines with new lead compounds. Our work shows
that the combination of NMR-based metabolomics and
genome mining is an efficient way to streamline the discovery
of novel molecules from actinomycetes. Prior knowledge of the
types of NPs that can be expected based on bioinformatics
thereby simplifies the chromatographic isolation process and
structure determination of target compound(s), while NMR
profiling of molecules in highly complex matrices allows rapid
linkage of chemotype to genotype. We here provide proof of
concept for this principle, whereby activation of the cryptic qin
type II PKS gene cluster by constitutive expression of its
pathway-specific activator gene (qin-ORF11) followed by
NMR-based metabolic profiling, identified novel glycosylated
pyranonaphthoquinones (1−5). The elucidated biosynthetic
pathway for the qinimycins in the genetically tractable
Streptomyces sp. MBT76 offers new insights into the biosyn-
thesis of this family of natural products. The best studied
pyranonaphtoquinone is undoubtedly actinorhodin produced
by Streptomyces coelicolor A3(2), which is the archetype of this
family of polyketides. The qinimycins described in this work
have intriguing structural features that make them stand out,
namely 8-C-glycosylation by the deoxyaminosugar D-foros-
amine, as well as 5,14-epoxidation and 13-hydroxylation.
Another novelty lies in the unusual fusion of the deoxy-
aminosugar to the pyranonaphthoquinone backbone during
biosynthesis of the antibiotics BE-54238 A and B. Thus, the
qinimycins form a new branch of the family of pyranonaph-
thoquinone-type antibiotics and provides important insights
into the biosynthesis of this class of natural products.
■ EXPERIMENTAL SECTION
General Experimental Procedures. FT-IR spectra were
recorded on a Shimadzu FT-IR 83000 spectrometer (Shimadzu
Corporation, Japan). UV measurements were performed using a
Shimadzu UV mini-1240 (Shimadzu Corporation, Japan). NMR
spectra were recorded in CD3OD on a Bruker 600 MHz calibrated to a
residual CD3OD (3.30 ppm). The UHPLC-TOF-MS analyses were
performed on an Ultimate 3000 UHPLC system (Thermoscientific,
Pittsburgh, PA, U.S.A.) coupled to a micro-ToF-2Q mass spectrometer
from Bruker Daltonics (Bremen, Germany) with an electrospray (ESI)
interface. HPLC analysis was performed with an Agilent 1200 series
HPLC apparatus (Agilent technologies Inc., Santa Clara, CA, U.S.A.),
using a 150 × 4.6 mm Luna 5 μm C18 (2) 100 Å column equipped
with a guard column containing C18 4 × 3 mm cartridges
(Phenomenex Inc., Torrance, CA, U.S.A.). Semipreparative HPLC
separation was performed on reversed-phase column (Phenomenex
Luna 5 μm C18 (2) 100 Å column, 250 × 10 mm). Silica gel 60 F254
(Merck, Darmstadt, Germany) was used for TLC analysis, migrated
with CHCl3/MeOH (10:1), and visualized with anisaldehyde/sulfuric
acid reagent. Polymerase chain reactions (PCR) were performed on a
T100 Thermal Cycler (Bio-Rad, Hercules, CA, U.S.A.). The ZR
Plasmid Miniprep-Classic kit (Zymo Research, Irvine, CA, U.S.A.) was
used for plasmid extraction. All organic solvents and chemicals were of
analytical or HPLC grade, depending on the experiment.
Bacterial Strains and Culturing Conditions. Streptomyces sp.
MBT76 was obtained from the culture collection of Molecular
Biotechnology, IBL, Leiden University. Escherichia coli JM10942 was
used for routine cloning. Escherichia coli ET1256743 containing
pUZ800244 was used for introducing nonmethylated DNA into
Streptomyces by conjugation. The basal medium for Streptomyces sp.
MBT76 growth was modified minimal liquid medium NMMP44
without PEG6000 and containing 1% (w/v) glycerol and 0.5% (w/v)
mannitol as the carbon sources, which was further supplemented with
0.8% (w/v) Bacto peptone.16 Tryptone soy broth with 10% (w/v)
sucrose (TSBS) was used to grow MBT76 mycelia as receptor for
conjugation experiments. Soy flour mannitol (SFM) agar plates44 were
used to grow overexpression conjugants of MBT76. For culturing of
MBT76 for chemical analysis, 50 mL modified NMMP was inoculated
with 106 spores of Streptomyces sp. MBT76 in 250 mL Erlenmeyer
flasks equipped with a spring, and grown at 30 °C with constant
shaking at 220 rpm. The incubation lasted for 120 h.
Genome Sequencing, Assembly, and Annotation. DNA was
extracted from Streptomyces sp. MBT76 as described previously.44
Genome sequencing and annotation was done essentially as described
previously.45 Illumina/Solexa sequencing on Genome Analyzer IIx and
sequencing on PacBio RS were outsourced to BaseClear BV (Leiden,
The Netherlands). In general, 100-nt paired-end reads were obtained,
and the quality of the short reads were verified using FastQC (http://
www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). Depending on the
quality, reads were trimmed to various lengths at both ends. Processed
raw reads were subsequently used as input for the Velvet assembly
algorithm. Genomes were annotated using the RAST server with
default options. Contigs were also annotated using GeneMark.hmm17
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for ORF prediction, BLASTP for putative function prediction, and
HMMER for protein-domain prediction, manually inspected for some
and visualized using Artemis. The genome has been deposited at
GenBank under the accession LNBE00000000.
Overexpression of the Pathway-Specific SARP Regulator
qin-ORF11. qin-ORF11 was amplified by PCR from Streptomyces sp.
MBT76 genomic DNA as descr ibed46 us ing pr imers
SC06_0044_F_EcoRI 5′-CGATGAATTCCGTCCGGCGCTTCG-
TGTG and SC06_0044_R_EcoRI_NdeI 5′-CGATGAATTCG-
CACCCGGTACAGGAGTGTGTCATATGCGATTCAACCT-
CATC. The PCR product was subcloned as an EcoRI fragment and
subsequently ligated as an NdeI-HindIII fragment behind the
constitutive ermE promoter in pSET152,29 which integrates at the
φC31 attachment site in the Streptomyces chromosome. The final
recombinant plasmid pCSW01 (pSET152/ermE/qin-ORF11) was
subsequently transformed into Escherichia coli ET12567/pUZ8002,
and the positive transformant was selected by 100 μg/mL apramycin.
This strain was then used to conjugate two-day old mycelia of
Streptomyces sp. MBT76. The ex-conjugant was confirmed by PCR
using primers SC06_0044_SF 5′-TTTCCCAGTCACGACGTTG
and SC06_0044_SR 5′-GGATAACAATTTCACACAGG.
Metabolomics and Compound Purification. Initially, 50 mL
cultures of Streptomyces sp. MBT76 or MBT76-1 were harvested by
centrifugation at 4000 rpm for 10 min, and the supernatant was
extracted twice with 20 mL of ethyl acetate (EtOAc). The organic
phase was washed with 30 mL of water and subsequently dried with 5
g of anhydrous Na2SO4. EtOAc was removed under vacuum at 38 °C,
and the residue was dissolved in 2.0 mL of EtOAc in a microtube
(Eppendorf type-5415C, Hamburg, Germany). The solvent was then
evaporated at room temperature under nitrogen gas and subsequently
dipped into liquid nitrogen and lyophilized using a freeze-dryer
(Edwards Ltd., Crawley, England). The NMR sample preparation and
measurements were performed according to our previously published
protocol.30 For details, see ref 47.
For separation of metabolites, 15 replicates of Streptomyces sp.
MBT76-1 culture (750 mL in total) were pooled. After EtOAc
extraction, 0.26 g of crude extract was partitioned between methanol
and n-hexane to remove the lipids. The resolved methanol fraction was
subsequently separated by semipreparative reversed-phase HPLC
(Phenomenex Luna 5 μm C18 (2) 100 Å column, 250 × 10 mm) on an
Agilent 1200 series HPLC (Agilent technologies Inc., Santa Clara, CA,
U.S.A.), eluting with a gradient of ACN in H2O adjusted with 0.1%
TFA from 20% to 60% at a flow rate of 2 mL/min in 40 min. Sixteen
fractions (Fr1−Fr16) were manually collected by peak detection at
254 nm, which were numbered in ascending order of retention time.
After rotary evaporation at 42 °C under vacuum, these 16 factions
were further subjected to 1H NMR profiling and UHPLC-UV-ToF-
MS analysis. Qinimycins were contained in Fr1 (2.1 mg) at retention
time 8.12 min.
Qinimycins (1−3). The products had the consistency of brown
gum; UV (MeOH) λmax (log ε) 222 (3.87), 270 (3.28), 326 (3.15)
nm; IR νmax 3400, 3299, 1792, 1674, 1585, 1304, 1202, 1148, 837, 800,
719 cm−1; 1H NMR (600 MHz, methanol-d4) and
13C NMR (150
MHz, methanol-d4) data, see Table 2; HRMS (positive mode) m/z
446.1854 [M + H]+ for qinimycin A (calcd for C23H28NO8, 446.1809),
464.1944 [M + H]+ for qinimycin B (calcd for C23H30NO9, 464.1915),
478.2097 [M + H]+ for qinimycin C (calcd for C24H32NO9, 478.2072).
UHPLC-UV-ToF-MS Analysis. UHPLC-ToF-MS analyses were
performed on an UHPLC system (Ultimate 3000, ThermoScientific,
Germany) coupled to an ESI-llQ-TOF spectrometer (micrOTOF-QII,
Bruker Daltonics, Germany) in the positive mode.48 The chromato-
graphic separation was done using a Kinetex C18 UHPLC 2.6 μm
particle size column 150 × 2.0 mm (Phenomenex) at a flow rate of 0.3
mL/min and a column temperature of 30 °C. Samples (3 μL) were
eluted using a gradient of solvent A (water) and B (acetonitrile), both
with 0.1% formic acid (v/v). The initial percentage of B was 5%, which
was linearly increased to 90% in 19.5 min, followed by a 2 min
isocratic period, and then re-equilibrated with original conditions in 2
min. Nitrogen was used as drying and nebulizing gas. The gas flow was
set at 10.0 L/min at 250 °C, and the nebulizer pressure was 2.0 bar.
The MS data were acquired over m/z range of 100−1000. The
capillary voltage was 3.5 kV. For internal calibration, a 10 mM solution
of sodium formate (Fluka, Steinheim, Germany) was infused. Formic
acid, water, and acetonitrile were LCMS grade (Optima, Fisher
Scientific, NJ, U.S.A.).
Antimicrobial Activity Assays. Antimicrobial activity of
qinimycins was determined according to a disc diffusion method as
described.49,50 Initially, 25 μL of Fr1 (2 mg/mL in methanol) was
spotted onto paper discs (6 mm diameter) placed on agar plates
containing a soft agar overlay with indicator bacteria. Indicator bacteria
were Bacillus subtilis 168, Escherichia coli ASD19, Staphylococcus aureus
CECT976, or Pseudomonas aeruginosa PAO1. Ampicillin and
apramycin were used as positive controls, whereby 5 μL was spotted
of a 1 mg/mL solution in miliQ water. The solvent methanol was used
as the negative control. After incubation at 37 °C for 18 h, growth
inhibition zones (in mm) were recorded as antimicrobial activity.
The MIC assay against B. subtilis and S. aureus was carried out in 96-
well plate by serial double dilution method, as previously described.15
All MIC determinations were performed in duplicate.
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